Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Inclusion Criteria:

• Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion Criteria:

• Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
• Planned intermittent or short-term (< 12 months) degarelix treatment
• Planned addition of, or switch to another form of androgen deprivation therapy during the study